<DOC>
	<DOCNO>NCT01199614</DOCNO>
	<brief_summary>This open-label study PTH ( 1-84 ) treatment seek : 1 . To determine action PTH ( 1-84 ) provide long term control serum calcium urinary calcium excretion use standard amount calcium vitamin D supplementation . 2 . To determine extent PTH ( 1-84 ) improve quality-of-life long-term basis . 3 . To establish safety PTH ( 1-84 ) administer 12 year . 4 . To attempt quantify improvement typical signs/symptoms hypoparathyroidism post PTH administration . There one visit conduct every six month study office principal investigator , Dr. John Bilezikian . In addition visit , , new patient use PTH ( 1-84 ) , Screening Visit four week prior baseline visit purpose perform screen labs well Pre-Baseline Local Quest Lab perform ensure stability prior Baseline .</brief_summary>
	<brief_title>HEXT ( Hypo EXTended ) : Effect PTH Skeleton Hypoparathyroidism</brief_title>
	<detailed_description>Hypoparathyroidism rare disorder parathyroid hormone ( PTH ) markedly decrease absent circulation . It remain hormone deficiency state replacement miss hormone heretofore unavailable . The hypoparathyroid state due either autoimmune destruction parathyroid glands loss parathyroid function neck surgery . Without PTH , calcium homeostasis markedly abnormal , salient clinical feature reduce serum calcium concentration . The hypocalcemia associate important abnormality markedly reduce parameter bone turnover . PTH ( 1-84 ) ideal therapeutic approach hypoparathyroidism . The current mainstay therapy , calcium vitamin D , important clinical limitation . Large dos calcium vitamin D require often associate hypercalciuria vitamin D toxicity . Moreover , approach correct skeletal deficiency resident bone due lack PTH . In contrast , PTH ( 1-84 ) replace precisely missing disorder . The research question : What long-term safety efficacy parameter PTH ( 1-84 ) therapy hypoparathyroidism ? Preliminary data suggest treatment PTH ( 1-84 ) 4 year improve control serum urine calcium concentration safely . Since hypoparathyroidism chronic disorder , important know whether salutary effect continue see beyond 4 year . There need determine safety efficacy treatment PTH ( 1-84 ) hypoparathyroidism beyond 4 year .</detailed_description>
	<mesh_term>Hypoparathyroidism</mesh_term>
	<criteria>For Returning Participants participant graduate one parent study : Must participate conclude CL111040 , PARC10007 PARC10008 Study site continental United States Must participate conclude Hypopara Study Columbia University failure complete either inclusionary study For New Participants ( 20 anticipate ) : INCLUSION CRITERIA : 1 . Signed date informed consent form ( ICF ) studyrelated procedure perform . 2 . Adult male females 18 85 year age . 3 . History hypoparathyroidism ≥ 18 month , include evidence hypocalcemia concomitant serum intact PTH concentration low limit normal within 12 month prior Baseline . 4 . Requirement calcitriol ≥0.25 mcg per day per day prior Baseline . 5 . Requirement supplemental oral calcium ≥ 1500 mg per day supplemental dietary source . 6 . Serum thyroid function test within normal laboratory limit screen subject receive thyroid hormone replacement therapy . For patient thyroid hormone replacement therapy , dose must stable least 3 month prior screen 7. serum creatinine &lt; 1.5 mg/dL single measurement prior use study drug 8 . Physically capable perform daily subcutaneous ( SQ ) selfinjections , thigh , study medication ( designee perform injection ) . 9 . Willingness ability comply protocol ( prior screening ) . 10 . With regard female patient : Women childbearing potential must negative pregnancy test Screening agree use two medically acceptable method contraception duration study pregnancy test every scheduled visit . EXCLUSION CRITERIA : Patients follow screen visit eligible enrollment study : 1 . Known history hypoparathyroidism result activate mutation CaSR gene impair responsiveness PTH ( pseudohypoparathyroidism ) . If unknown , shall assume notpresent . 2 . Any disease might affect calcium metabolism calciumphosphate homeostasis hypoparathyroidism , active hyperthyroidism , Paget 's disease , insulindependent diabetes mellitus ( IDDM ) poorly control Type II diabetes mellitus ( HbA1C &gt; 8 % ) , severe chronic cardiac , liver renal disease , Cushing 's syndrome , neuromuscular disease rheumatoid arthritis , myeloma , pancreatitis , malnutrition , rickets , recent prolonged immobility , active malignancy , primary secondary hyperparathyroidism , history parathyroid carcinoma , hypopituitarism , acromegaly , multiple endocrine neoplasia type I II . 3 . To eligible , patient history thyroid cancer must document diseasefree period least 5 year ( 2 year evidence follow doctor 's note clearance ) . 4 . Patients dependent regular parenteral calcium infusion ( e.g . calcium gluconate ) maintain calcium homeostasis . 5 . Patients undergone gastric resection active peptic ulcer disease require medical therapy . 6 . Use prohibit medication , raloxifene hydrochloride , lithium , methotrexate , systemic corticosteroid within last 6 month . 7 . Treatment PTHlike drug , include PTH ( 184 ) , PTH ( 134 ) N terminal fragment analog PTH PTHrelated protein within last 6 month . 8 . Other drug know influence calcium bone metabolism , calcitonin , sodium fluoride , cinacalcet hydrochloride within last 6 month . 9 . Use oral bisphosphonates within previous 6 month IV bisphosphonate preparation within previous 12 month prior screen . 10 . Seizure disorder/epilepsy history document seizure within previous 6 month . 11 . In regard participant 18 21 year age : Presence open epiphysis determine xray . 12 . Radiotherapy skeleton within 5 year . 13 . Serum 25hydroxyvitamin D level great 1.5fold laboratory upper limit normal . ( i.e. , &gt; 150 ng/mL ) 14 . Any disease condition opinion Investigator high probability preclude patient complete study patient appropriately comply study requirement . 15 . Participation investigational trial receipt investigational drug device occur within 6 month prior screen study . 16 . Pregnant lactating woman . 17 . History diagnosed drug alcohol dependence within previous 3 year . 18 . Clinical history renal calculus within past 6 month . 19 . Any condition negatively affect gastrointestinal absorption , include limited short bowel syndrome , bowel resection , tropical sprue , celiac disease , ulcerative colitis , Crohn 's disease . 20 . Chronic/severe cardiac disease include limited cardiac insufficiency , arrhythmia , bradycardia ( rest heart rate &lt; 60 beats/minute ) , hypotension ( systolic diastolic blood pressure &lt; 100 60 mmHg , respectively ) . 21 . History cerebrovascular accident ( CVA ) past 5 year earlier , residual impairment would affect participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypoparathyroidism</keyword>
	<keyword>Hypopara</keyword>
	<keyword>HPTH</keyword>
	<keyword>Hypocalcemia</keyword>
	<keyword>Hypercalciuria</keyword>
	<keyword>PTH</keyword>
	<keyword>PTH ( 1-84 )</keyword>
</DOC>